https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2013-09-25 15:53:142016-12-01 12:44:062013 ASH: DNA Demethylation Activity over time and safety regimens of SGI-110 in r/r MDS and AML pts
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2013-08-25 15:53:402016-12-01 12:44:222013 Cell Symposia: Cancer Epigenomics. Anti-tumour Activity of SGI-110, a Novel Hypomethylating
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2013-05-25 15:55:112016-12-01 12:45:502013 EHA: Outcomes of intermediate or high risk MDS patients post azacitidine and or decitabine
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2013-04-25 15:55:412016-12-01 12:46:052013 AACR: Novel Small Molecule DNA Methylation Inhibitor SGI-110 as Ovarian Cancer Chemosensitizer
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2013-04-25 10:56:152016-12-01 12:46:222013 AACR: In vivo immunomodulatory activity of SGI-110, a second generation hypomethylating agent
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2013-02-25 15:57:202016-12-01 12:46:532013 TAT: IMMUNOMODULATORY ACTIVITY OF SGI-110, A SECOND GENERATION HYPOMETHYLATING AGENT
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2012-11-25 15:59:072016-12-01 12:37:192012 ASH: Results from Dose Escalation Phase of Randomized Phase 1-2 FIH Study of SGI-110
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
